Regional blood-brain barrier dysfunction maps to lower performance in cognitive ageing.
9 affiliations
- 1Department of Medical Neuroscience and the Brain Repair Center, Dalhousie University, Faculty of Medicine, Halifax, NS B3H 4R2, Canada.
- 2Departments of Physiology and Cell Biology, The Zelman Center for Brain Science Research, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
- 3Faculty of Health Sciences, Joyce & Irving Goldman Medical School at Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
- 4Faculty of Social Work, Ashkelon Academic College, Ashkelon 78211, Israel.
- 5Department of Psychiatry, Soroka University Medical Center, Beer-Sheva 8410101, Israel.
- 6Department of Diagnostic Imaging, Soroka University Medical Center, Beer Sheva 8410101, Israel.
- 7Neurophysiology of Epilepsy Unit, NINDS, National Institutes of Health, Bethesda, MD 20892, USA.
- 8Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia 19104, USA.
- 9Center of Neuroscience, The Chaim Sheba Medical Center, Ramat-Gan 5265601, Israel.
Abstract
Age-related cognitive decline is a common and growing public health challenge, associated with loss of independence, reduced quality of life, increased caregiver burden and substantial healthcare and societal costs. Yet cognitive decline in ageing is heterogeneous, and current clinical constructs do not reliably capture the underlying biological mechanisms or predict progression to dementia. This cross-sectional study examined whether blood-brain barrier dysfunction (BBBD) provides a biologically supported correlate of cognitive performance beyond clinical diagnosis. The study included 46 patients with mild cognitive impairment (MCI), 46 age-matched controls and 43 young controls. BBBD was assessed using dynamic contrast-enhanced MRI in 42 patients with MCI and all controls, alongside volumetric brain analysis. Standardized NeuroTrax cognitive assessment data were analysed for 41 MCI patients and 19 age-matched controls. BBBD was analysed using the BBBdetect software (Emagix Inc, Nova Scotia, Canada), quantifying voxelwise and region-wise blood-brain barrier permeability; volumetric analysis was performed using the Volbrain software; and cognitive performance was stratified into low- and high-performance subgroups based on modified z-scores. Compared with young controls, the older cohort (MCI patients combined with age-matched controls) showed significantly greater BBBD volume and regional extent. Permeability increased with age and showed marked inter-individual variability. Across participants, lower cognitive performance was associated with a greater number of regions exhibiting BBBD. Receiver operating characteristic analysis identified domain-specific spatial patterns of BBBD linked to poor performance in memory, executive, attention, verbal and motor domains, implicating frontal, cingulate, hippocampal, basal ganglia and cerebellar regions. In contrast, volumetric analyses revealed expected age-related reductions in grey and white matter and cortical thickness along with increased ventricular volume; however, these structural changes showed weak to no associations with cognitive performance. These findings suggest that BBBD is widespread in ageing and that regional BBBD maps to domain-specific cognitive deficits. BBBD thus emerges as a biologically relevant biomarker of age-related cognitive impairment and a potential therapeutic target for preserving cognitive function in ageing.
Related
- Strengthening healthy ageing in the Caribbean through regional capacity building and ICOPE implementation
- Active ageing across the retirement transition in Korea: regional trajectories and risk of low active ageing
- Neuropsychiatric symptom clusters and plasma proteomic signatures across cognitive ageing and dementia in Kinshasa, Democratic Republic of the Congo: a cross-sectional analysis of the EVCD-RDC cohort
- Targeting Specific Sirtuin Modulation: Emerging Therapeutic Strategies for Healthy Cognitive Ageing and Potential Implications for Alzheimer’s Disease
- A productivist drift of active ageing policies in Italy: regional inequality and economic growth in 2007–2018
BibTeX
@article{mirloo2026regional,
title = {{Regional blood-brain barrier dysfunction maps to lower performance in cognitive ageing.}},
author = {Sheida Mirloo and Sheizaf Shpilberg and Noam Druker and Rotem Saar-Ashkenazy and Ofer Prager and Shai Baruch Neustaedter and Gal Ben-Arie and Ilan Shelef and Lyna Kamintsky and Yonatan Serlin and Danielle K Sandsmark and Alon Friedman and Hadar Shalev},
journal = {Brain communications},
year = {2026},
month = oct,
doi = {10.1093/braincomms/fcag342},
url = {https://europepmc.org/article/MED/42909898},
note = {CC BY},
}
RIS
TY - JOUR
TI - Regional blood-brain barrier dysfunction maps to lower performance in cognitive ageing.
AU - Sheida Mirloo
AU - Sheizaf Shpilberg
AU - Noam Druker
AU - Rotem Saar-Ashkenazy
AU - Ofer Prager
AU - Shai Baruch Neustaedter
AU - Gal Ben-Arie
AU - Ilan Shelef
AU - Lyna Kamintsky
AU - Yonatan Serlin
AU - Danielle K Sandsmark
AU - Alon Friedman
AU - Hadar Shalev
PY - 2026
DA - 2026/10/21
JO - Brain communications
DO - 10.1093/braincomms/fcag342
UR - https://europepmc.org/article/MED/42909898
AB - Age-related cognitive decline is a common and growing public health challenge, associated with loss of independence, reduced quality of life, increased caregiver burden and substantial healthcare and societal costs. Yet cognitive decline in ageing is heterogeneous, and current clinical constructs do not reliably capture the underlying biological mechanisms or predict progression to dementia. This cross-sectional study examined whether blood-brain barrier dysfunction (BBBD) provides a biologically supported correlate of cognitive performance beyond clinical diagnosis. The study included 46 patients with mild cognitive impairment (MCI), 46 age-matched controls and 43 young controls. BBBD was assessed using dynamic contrast-enhanced MRI in 42 patients with MCI and all controls, alongside volumetric brain analysis. Standardized NeuroTrax cognitive assessment data were analysed for 41 MCI patients and 19 age-matched controls. BBBD was analysed using the BBBdetect software (Emagix Inc, Nova Scotia, Canada), quantifying voxelwise and region-wise blood-brain barrier permeability; volumetric analysis was performed using the Volbrain software; and cognitive performance was stratified into low- and high-performance subgroups based on modified z-scores. Compared with young controls, the older cohort (MCI patients combined with age-matched controls) showed significantly greater BBBD volume and regional extent. Permeability increased with age and showed marked inter-individual variability. Across participants, lower cognitive performance was associated with a greater number of regions exhibiting BBBD. Receiver operating characteristic analysis identified domain-specific spatial patterns of BBBD linked to poor performance in memory, executive, attention, verbal and motor domains, implicating frontal, cingulate, hippocampal, basal ganglia and cerebellar regions. In contrast, volumetric analyses revealed expected age-related reductions in grey and white matter and cortical thickness along with increased ventricular volume; however, these structural changes showed weak to no associations with cognitive performance. These findings suggest that BBBD is widespread in ageing and that regional BBBD maps to domain-specific cognitive deficits. BBBD thus emerges as a biologically relevant biomarker of age-related cognitive impairment and a potential therapeutic target for preserving cognitive function in ageing.
SN - 2632-1297
ER -